TY - JOUR
T1 - Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010
AU - Yamaguchi, Keizo
AU - Ishii, Yoshikazu
AU - Tateda, Kazuhiro
AU - Shimizu, Chikara
AU - Suwabe, Akira
AU - Kaku, Mitsuo
AU - Hishinuma, Akira
AU - Maesaki, Shigefumi
AU - Kobayashi, Yoshio
AU - Kondo, Shigemi
AU - Matsumoto, Tetsuya
AU - Iwata, Morihiro
AU - Kawakami, Sayoko
AU - Otsuka, Yoshihito
AU - Maekawa, Masato
AU - Yagi, Tetsuya
AU - Yamagishi, Yuka
AU - Fujita, Shinichi
AU - Hida, Yukio
AU - Nakatani, Kaname
AU - Ichiyama, Satoshi
AU - Fujimoto, Ikuko
AU - Kohno, Hisashi
AU - Takahashi, Hakuo
AU - Kusano, Nobuchika
AU - Kurokawa, Yukinori
AU - Watanabe, Yaeko
AU - Negayama, Kiyoshi
AU - Miyamoto, Hitoshi
AU - Kiyosuke, Makiko
AU - Mashiba, Kouichi
AU - Yanagihara, Katsunori
AU - Aoki, Yosuke
AU - Hiramatsu, Kazufumi
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2013/11
Y1 - 2013/11
N2 - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60% of staphylococci and 11.1% of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8%, 3.9% and 12.8%, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5%, 1.0% and 3.3%, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9% in P. aeruginosa to 100% in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.
AB - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60% of staphylococci and 11.1% of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8%, 3.9% and 12.8%, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5%, 1.0% and 3.3%, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9% in P. aeruginosa to 100% in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.
KW - Susceptibility
KW - Tazobactam/piperacillin
KW - β-lactamase
UR - http://www.scopus.com/inward/record.url?scp=84890252760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890252760&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:84890252760
VL - 61
SP - 514
EP - 525
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - 6
ER -